Table 8.
The specific therapeutical program of all patients before and after R0 resection
| Patients | Conversion therapies | Adjuvant therapies | |
|---|---|---|---|
| Modalities | Intervals (days after the surgery) |
||
| 1 | HAIC + Lenvatinib + Camrelizumab | No | - |
| 2 | HAIC + Lenvatinib + Camrelizumab | Lenvatinib + Camrelizumab | 29 |
| 3 | HAIC + Lenvatinib + Camrelizumab | No | - |
| 4 | HAIC + Lenvatinib + Camrelizumab | Lenvatinib + Tislelizumab | 40 |
| 5 | HAIC + Lenvatinib + Camrelizumab | Lenvatinib + Camrelizumab | 33 |
| 6 | HAIC + Lenvatinib + Camrelizumab | Lenvatinib + Camrelizumab | 42 |
| 7 | TACE + Lenvatinib + Camrelizumab | TACE+Lenvatinib + Tislelizumab | 41 |
| 8 | HAIC + Lenvatinib + Camrelizumab | Tislelizumab | 43 |
| 9 | HAIC + Lenvatinib + Camrelizumab | No | - |
| 10W&W | HAIC + Apatinib + Camrelizumab | No | - |
| 11W&W | HAIC + Apatinib + Camrelizumab | Camrelizumab | - |
| 12 | HAIC + Lenvatinib + Camrelizumab | TACE + Lenvatinib + Camrelizumab | 33 |
| 13 | HAIC + Lenvatinib + Camrelizumab | Lenvatinib + Camrelizumab | 30 |
| 14 | HAIC + Apatinib + Camrelizumab | TACE + Lenvatinib + Camrelizumab | 41 |
| 15 | TACE + Radiotherapy+ Lenvatinib | TACE + Lenvatinib | 50 |
| 16 | TACE + Lenvatinib + Camrelizumab | No | - |
| 17 | HAIC + Lenvatinib + Camrelizumab | Lenvatinib + Camrelizumab | 35 |
| 18 | TACE + Apatinib + Camrelizumab | Apatinib + Camrelizumab | 37 |
| 19 | TACE + Sorafenib + Camrelizumab | Camrelizumab | 39 |
| 20 | TACE + Apatinib + Camrelizumab | Apatinib + Camrelizumab | 43 |
| 21 | TACE + Lenvatinib | Lenvatinib | 35 |
| 22 | TACE + Lenvatinib | Lenvatinib | 60 |
| 23 | TACE + Sorafenib +Sintilimab | TACE + Sorafenib + Sintilimab | 33 |
| 24W&W | TACE + Sorafenib + Camrelizumab | Sorafenib + Camrelizumab | - |
| 25 | Sorafenib+ Sintilimab | Sintilimab | 28 |
| 26 | TACE + Lenvatinib | Lenvatinib | 12 |
W&W watch & wait